|
(6bR,10aS)-α-(4-Fluorophenyl)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-butanol Suppliers list
|
| Company Name: |
TLC Pharmaceutical Standards Ltd.
|
| Tel: |
18012923235; 18012923235 |
| Email: |
chinasales04@tlcstandards.com.cn |
| Products Intro: |
Product Name:Lumateperone Impurity 24
CAS:1469777-40-9
Purity:95%+ HPLC Package:10mg;25mg;50mg;100mg
|
|
| | (6bR,10aS)-α-(4-Fluorophenyl)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-butanol Basic information |
| Product Name: | (6bR,10aS)-α-(4-Fluorophenyl)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-butanol | | Synonyms: | Lumateperone Impurity 46 | | CAS: | 1469777-40-9 | | MF: | C23H28FN3O | | MW: | 381.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1469777-40-9.mol | ![(6bR,10aS)-α-(4-Fluorophenyl)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-butanol Structure](CAS/20210305/GIF/1469777-40-9.gif) |
| | (6bR,10aS)-α-(4-Fluorophenyl)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-butanol Chemical Properties |
| Boiling point | 551.7±50.0 °C(Predicted) | | density | 1.28±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | pka | 14.28±0.20(Predicted) |
| | (6bR,10aS)-α-(4-Fluorophenyl)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-butanol Usage And Synthesis |
| Uses | Lumateperone metabolite 1 (Formula T) is a metabolite of Lumateperone (HY-17637)[1]. Lumateperone (ITI-007) is an orally active 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator[2][3] | | References | [1] Sharon Mates, et al. Organic compounds. WO2015154025A1.
[2] Jinyuan Zhang, et al. Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth. Mol Inform. 2022 Mar 30:e2200011. DOI:10.1002/minf.202200011
[3] J Titulaer, et al. Lumateperone-mediated effects on prefrontal glutamatergic receptor-mediated neurotransmission: A dopamine D1 receptor dependent mechanism. Eur Neuropsychopharmacol. 2022 Jul 22;62:22-35. DOI:10.1016/j.euroneuro.2022.06.009 |
| | (6bR,10aS)-α-(4-Fluorophenyl)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-butanol Preparation Products And Raw materials |
|
|
Tag:(6bR,10aS)-α-(4-Fluorophenyl)-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxaline-8(7H)-butanol(1469777-40-9)
Related Product Information
|